GLICLAVAC MV 0.3

GLICLAVAC MV 0.3 is a triple combination oral antidiabetic medication that contains Gliclazide 80 mg, Metformin 500 mg, and Voglibose 0.3 mg, specially formulated for the management of type 2 diabetes mellitus.

• Gliclazide stimulates insulin secretion from the pancreas.

• Metformin enhances insulin sensitivity and lowers glucose production in the liver.

• Voglibose delays carbohydrate absorption in the intestine, helping prevent post-meal sugar spikes.
  Together, these ingredients provide comprehensive and sustained blood sugar control throughout the day.

Key Benefits:

• Triple-action control for fasting and post-meal blood sugar.

• Helps improve insulin sensitivity and glucose metabolism.

• Reduces the risk of blood sugar fluctuations.

• Suitable for patients who require enhanced glycemic control.